


VeraBIND Tau

In recent years, advancements in medicine have transformed the methods for diagnosis of Alzheimer's disease (AD) and other dementias. Highly sensitive blood-based biomarkers now detect what once required invasive spinal taps or costly tau positron emission tomography (PET) scans. With new therapies emerging and growing insights into disease prevention, early

The VeraBIND™ Tau assay addresses the critical unmet need for minimally invasive and cost-effective tests for early detection of AD¹. By detecting active tau pathology—often present before symptoms arise²⁻⁴—this innovative assay provides a reliable method for earlier diagnosis and intervention. Early detection empowers physicians and patients to take proactive steps, including therapeutic planning and lifestyle adjustments, which may help slow disease progression and improve quality of life.



Understanding Tau Pathology

Tau pathology, marked by the accumulation of abnormal tau proteins forming neurofibrillary tangles⁵, disrupts brain cell functions and contributes to cognitive decline in AD. It serves as a key marker for early diagnosis, distinguishing AD from other neurodegenerative conditions. While tau PET imaging is the most accurate method for detecting insoluble tau aggregates and predicting cognitive decline, its high cost and limited accessibility highlight the need for more practical, biomarker-based approaches⁶.

How VeraBIND Tau is Different

While biomarkers like amyloid plaques are not entirely specific to AD⁷, they can assess risk of disease, track progression, and, in cases of measurable cognitive decline, identify its underlying cause.

By contrast, VeraBIND Tau identifies active tau pathology, which is the hallmark of disease⁸, and provides an answer to whether hyperphosphorylated (misfolded) tau is actively binding to normal tau. Additionally, as a blood-based test, VeraBIND Tau provides a practical alternative to costly and limited tau PET imaging, ensuring broader availability and an improved patient experience.

The Intended Use

The VeraBIND Tau assay measures the pathological activity of hyperphosphorylated tau in blood samples of cognitively normal individuals or individuals experiencing cognitive impairment. Results can be used to aid in the diagnosis of Alzheimer's disease.

Testing Process

Sample collection kits can be sent to you or your patients.



1. Upon receipt of the collection kit, an appointment will need to be scheduled at a pre-designated laboratory.



2. During the appointment a single vial of blood is drawn and shipped overnight to a central lab.



3. The sample is analyzed upon receipt by the central lab, using proprietary VeraBIND™ technology.



4. Results are returned to the clinician within two weeks.

Understanding Test Results: Guidance for Clinicians

Interpreting a Positive Test Result

A positive VeraBIND Tau result indicates the presence of active tau pathology, suggesting an elevated risk of AD. This result provides an opportunity to take proactive steps by ordering additional diagnostic tests to confirm or refine the diagnosis, discussing potential enrollment in clinical trials for emerging therapies, and initiating personalized treatment plans that may include pharmacologic and non-pharmacologic interventions. Additionally, evidence-based lifestyle modifications can be recommended to slow disease progression and improve patient outcomes.

Interpreting a Negative Test Result

A negative result offers reassurance, particularly for patients without symptoms of cognitive decline. However, it does not completely eliminate the risk of future neurodegenerative conditions. Based on the patient's medical history and individual risk factors, regular monitoring and follow-up assessments may be warranted. Addressing other contributing factors to cognitive health and educating patients on strategies to preserve brain health over time are also important steps to ensure long-term care and prevention.

This clinical tool enables you to make informed decisions for your patients, ensuring early intervention and personalized care where appropriate.

Take the Next Step in Cognitive Health Care

Empower your practice with the VeraBIND Tau assay—a simple, effective tool to aid in the early diagnosis of Alzheimer's disease.



**Join Our
Early Access
Program**

The VeraBIND Tau assay was developed and validated in our CLIA certified partner lab. This test has not been cleared or approved by the US FDA or CE marked in the EU as an in vitro diagnostic test.

© 2024 Veravas, Inc. All rights reserved. All trademarks are the property of Veravas, Inc.

References

1. Li TR et al. *Curr Neuroparmacol*. 2022;20(4):713-737
2. Braak H et al. *Acta Neuropathol*. 112, 389–404 (2006)
3. Braak H et al. *J. Neuropathol. Exp. Neurol* 70, 960–969 (2011).
4. Wharton SB et al. *Acta Neuropathol. Commun* 4, 11 (2016).
5. Medeiros R et al. *CNS Neurosci Ther*. 2011;17(5):514-524.
6. Frontzkowski, L. et al. *Nat Commun* 13, 4899 (2022).
7. Wolfe KJ et al. *Semin Cell Dev Biol*. 2011;22(5):476-481.
8. Thal DR et al. *Brain Res Bull*. 2022;190:204-217.